Gilead’s long-acting HIV treatment is a ‘step, not a leap’
A new treatment from Gilead Sciences demonstrated a long-lasting effect on HIV after a single dose, suggesting a future in which patients could forego daily pills in favor of a twice-a-year injection. But experts say there’s a long road ahead before the standard of could change.
As STAT’s Natalya Ortolano reports, a small study of Gilead’s lenacapavir found that the drug persisted in patients’ blood up to six months after a single dose. The treatment targets an HIV protein called capsid, weakening the virus’s outer coating to disable infection.
But lenacapavir is unlikely to be useful as a monotherapy, experts said, as it might allow the virus to develop resistance without the aid of other drugs. That makes the treatment “a step, not a leap,” said Baird analyst Brian Skorney. Gilead will need to develop long-acting treatments that prevent resistance before lenacapavir can become a go-to treatment for HIV.
Read more.
As STAT’s Natalya Ortolano reports, a small study of Gilead’s lenacapavir found that the drug persisted in patients’ blood up to six months after a single dose. The treatment targets an HIV protein called capsid, weakening the virus’s outer coating to disable infection.
But lenacapavir is unlikely to be useful as a monotherapy, experts said, as it might allow the virus to develop resistance without the aid of other drugs. That makes the treatment “a step, not a leap,” said Baird analyst Brian Skorney. Gilead will need to develop long-acting treatments that prevent resistance before lenacapavir can become a go-to treatment for HIV.
Read more.
No hay comentarios:
Publicar un comentario